Objective Capital Management’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$431K Sell
3,354
-239
-7% -$28K 0.38% 60
2026
Q1
$432K Buy
3,593
+450
+14% +$52K 0.44% 59
2025
Q4
$331K Hold
3,143
0.34% 64
2025
Q3
$264K Hold
3,143
0.27% 73
2025
Q2
$249K Sell
3,143
-96
-3% -$7.63K 0.28% 70
2025
Q1
$291K Sell
3,239
-1,324
-29% -$124K 0.37% 62
2024
Q4
$454K Sell
4,563
-335
-7% -$34.5K 0.3% 68
2024
Q3
$556K Buy
+4,898
New +$582K 0.33% 65
2024
Q1
$623K Buy
4,723
+20
+0.4% +$2.46K 0.42% 55
2023
Q4
$513K Sell
4,703
-107
-2% -$11.1K 0.39% 58
2023
Q3
$495K Sell
4,810
-124
-3% -$13.4K 0.44% 53
2023
Q2
$569K Buy
4,934
+140
+3% +$15.9K 0.5% 47
2023
Q1
$510K Buy
4,794
+341
+8% +$36.8K 0.47% 50
2022
Q4
$494K Sell
4,453
-5
-0.1% -$511 0.49% 51
2022
Q3
$384K Buy
4,458
+15
+0.3% +$1.34K 0.41% 57
2022
Q2
$405K Sell
4,443
-7
-0.2% -$621 0.41% 58
2022
Q1
$365K Sell
4,450
-84
-2% -$6.62K 0.28% 79
2021
Q4
$348K Buy
+4,534
New +$361K 0.25% 79

Other funds holding MRK

Objective Capital Management's MRK Position: Q2 2026 in Review

Objective Capital Management reduced its Merck (MRK) stake by 6.7% in Q2 2026, selling an estimated $28K and leaving 3,354 shares worth $431K. The position accounts for 0.38% of the portfolio, ranked #60.

Objective Capital Management first reported a position in MRK in Q4 2021 and has held it in 18 quarters since. The position peaked at $623K in Q1 2024. 810 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Objective Capital Management held 3,354 shares of Merck worth $431K as of Q2 2026.
  • Objective Capital Management sold 239 Merck shares in Q2 2026, an estimated $28K.
  • Merck made up 0.38% of Objective Capital Management's portfolio in Q2 2026, its #60 holding.
  • Objective Capital Management first reported a position in Merck in Q4 2021 and has held it in 18 quarters since.
  • Objective Capital Management's Merck position peaked at $623K in Q1 2024.
  • 810 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Objective Capital Management's 13F filing for Q2 2026, filed 20 Jul 2026.